FREQUENTLY ASKED QUESTIONS
Research Peptide Fundamentals — Common Questions Answered
Plain-language answers drawn from peer-reviewed research, with citations. Not medical advice.
What does BPC-157 do in the body?
In animal studies, BPC-157 appears to accelerate tissue healing by promoting the growth of new blood vessels (angiogenesis) — specifically by up-regulating the VEGFR2 receptor and activating downstream VEGFR2-Akt-eNOS signaling [4]. It has also been described as modulating serotonergic and dopaminergic neurotransmitter systems and the brain-gut axis [7]. In humans, evidence is extremely limited: as of 2025 only three small pilot studies have been conducted, and no large, rigorous controlled trials exist [2].
Is BPC-157 a growth hormone?
No. BPC-157 is a gastric pentadecapeptide — a 15-amino-acid sequence derived from a protein in human gastric juice. It is not a growth hormone, a growth hormone analog, or a growth hormone secretagogue. It is categorized as a cytoprotective and potentially pro-angiogenic research peptide [2][4]. Claims that it raises growth hormone levels are not supported by the published literature; it is sometimes noted that it sensitizes growth-hormone receptors in tendon fibroblasts, but this is a local, cell-level finding, not systemic GH elevation.
Does BPC-157 work immediately?
There is no controlled human data establishing an onset timeline for BPC-157. In rodent models, effects on healing parameters have been documented over periods ranging from days to weeks, depending on the tissue and endpoint. In uncontrolled research-use community reports, people describe noticing changes in tendon and joint comfort within one to three weeks, but these are anecdotal self-reports with no clinical verification, not clinical evidence of an onset time [2].
Does BPC-157 damage the liver?
The available evidence does not support hepatotoxicity. In the only published first-in-human IV safety pilot (n=2), BPC-157 infusion up to 20 mg produced no measurable changes in hepatic biomarkers [1]. Animal studies have not documented hepatotoxic effects. A 2025 review characterizes the current safety signals as reassuring within a very small and mostly preclinical dataset [2]. However, the absence of evidence of harm in a tiny dataset is not the same as established safety; long-term human data do not exist.
What does Retatrutide do?
Retatrutide is an investigational triple-agonist compound that simultaneously activates three hormone receptors: the GIP receptor, the GLP-1 receptor, and the glucagon receptor [8][9]. The GLP-1 and GIP arms suppress appetite and improve glucose-dependent insulin secretion; the glucagon-receptor arm adds energy expenditure and fat mobilization. In 48-week Phase 2 trials in humans, this combination produced a mean body-weight reduction of -24.2% at the highest tested dose [11] and an -82.4% liver-fat reduction in a steatotic liver disease substudy [10].
How does Retatrutide work?
Retatrutide binds and activates three incretin and metabolic hormone receptors — GIPR, GLP-1R, and GCGR — through a single peptide molecule. Cryo-EM structural analysis confirmed binding at all three receptors at sub-3-Å resolution [9]. Its relative potencies differ from native hormones: approximately 8.9-fold more potent at GIPR than native GIP, and approximately 0.3- and 0.4-fold at GCGR and GLP-1R respectively. The glucagon-receptor component is distinctive — it drives thermogenesis and energy expenditure through cAMP/PKA signaling, contributing to weight loss beyond what GLP-1-only agents produce [8].
Is Retatrutide FDA approved?
No. As of mid-2026, Retatrutide is an investigational compound in Phase 3 clinical trials (the TRIUMPH program). It has not been approved by the FDA or any other regulatory agency for any indication [8][11]. It cannot be legally prescribed, and material sold outside clinical trials is of unverified identity and purity. The FDA issued over 50 warning letters to retatrutide vendors in 2025 for Federal FD&C Act violations.
What is Ipamorelin?
Ipamorelin is a synthetic pentapeptide agonist of the ghrelin receptor (GHS-R1a) on pituitary cells. It triggers a discrete pulse of growth hormone (GH) release without meaningfully raising cortisol or prolactin — unlike earlier GH-releasing peptides such as GHRP-6. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2 [16]. It has never been approved as a drug; its only Phase 2 human trial (for postoperative ileus) failed its primary endpoint [15].
What does Ipamorelin do for you?
In a controlled human pharmacokinetic study, ipamorelin produced a single discrete GH pulse peaking approximately 40 minutes after IV dosing [16]. In animal models, subcutaneous dosing dose-dependently increased longitudinal bone growth rate [17]. The one Phase 2 human trial did not demonstrate a statistically significant effect on its endpoint (time to first tolerated meal after bowel resection) [15]. Claims about anti-aging, fat loss, or muscle building in humans are not supported by the peer-reviewed evidence base; they reflect mechanism-level extrapolation from animal data.
What are the risks of Ipamorelin?
Key risks documented in the literature: (1) the growth hormone/IGF-1 axis theoretically raises concern in anyone with active or recent malignancy [17]; (2) GH is a counter-regulatory hormone that reduces insulin sensitivity, combined with ipamorelin's documented ex vivo insulinotropic effect on pancreatic islets, creating unpredictable glycemic risk in people with diabetes or insulin resistance; (3) a 28-day study of a related GHS-R1a agonist found dose-dependent myocardial degeneration in rats [14] — ipamorelin's long-term cardiovascular safety in humans is uncharacterized; (4) it is prohibited in sport under WADA S2 [15].
What does a GHK-Cu peptide do?
GHK-Cu (Copper Tripeptide-1) stimulates dermal fibroblasts to synthesize collagen, elastin, glycosaminoglycans, and the proteoglycan decorin [21]. It rebalances matrix metalloproteinase activity against TIMP inhibitors, supporting tissue remodeling. At the gene-expression level, a Connectivity Map analysis reported that GHK alters expression of approximately 31.2% of human genes at a ≥50% change threshold, with upregulation of wound-repair, DNA-repair, antioxidant, and ubiquitin-proteasome pathways and suppression of NF-kB-driven inflammatory gene sets [19].
What is the difference between GHK and GHK-Cu?
GHK is the plain tripeptide (Gly-His-Lys) without a metal. GHK-Cu is the same tripeptide chelated 1:1 to a copper(II) ion. The copper coordination is mechanistically necessary for most of the documented bioactivities: the plain GHK peptide does not reproduce key effects such as matrix metalloproteinase-2 stimulation documented with the copper-bound form. The Cu(II) ion also enables lysyl oxidase-mediated collagen and elastin cross-linking and provides antioxidant activity that the plain GHK lacks. In cosmetic and research literature, the active form is GHK-Cu, not free GHK.
Is GHK-Cu peptide really anti-aging?
The term 'anti-aging' in a medical or longevity sense is not supported by controlled human evidence for GHK-Cu. What the controlled human evidence shows is: (1) collagen production increased in approximately 70% of topically treated subjects versus 50% for vitamin C and 40% for retinoic acid [18][21]; (2) a 6-month RCT of a GHK-containing complex showed significant hair-count improvement over placebo in men with androgenetic alopecia [20]; and (3) improvements in skin laxity, fine lines, and wrinkle depth have been documented in controlled topical studies. These are skin-level findings, mostly small-scale, predominantly from one investigator group, and limited to topical use.
What is NAD+ supplement used for?
NAD+ and its precursors (NMN and NR) are marketed for cellular energy support, cognitive function, and longevity. The supporting science is that NAD+ is the cell's central redox carrier and the substrate for sirtuins and PARP1, which govern DNA repair and gene regulation; tissue NAD+ declines with aging [26]. A multicenter RCT of NMN demonstrated improved walking distance and quality-of-life scores alongside blood NAD+ elevation [24]; an NMN trial showed improved muscle insulin sensitivity in prediabetic women [25]. The 2025 Nature Metabolism review [23] found that translation to hard clinical outcomes is inconsistent and noted the need for more tissue-specific human data.
What is the downside of taking NAD+?
Several concerns merit attention: (1) oral NAD+ itself is poorly bioavailable intact; precursors NMN and NR are considered more rational [26]; (2) IV compounded NAD+ has been subject to a Class I FDA recall for bacterial endotoxin contamination; (3) a theoretical concern exists that boosting NAD+ could fuel the metabolism of proliferating cancer cells; (4) NMN faces FDA regulatory uncertainty about its supplement status; and (5) supplement-grade products vary widely in actual content and purity. In controlled clinical trials, NR at up to 1000 mg/day for 8 weeks produced no flushing and no significant adverse events versus placebo [27].
Does NAD+ cause weight gain?
The published controlled trial evidence does not document NAD+ precursor supplementation causing weight gain. In the NMN insulin-sensitivity RCT in prediabetic women, there was no significant change in body composition [25]. In the multicenter NMN RCT, no weight-gain signal was noted [24]. The NR safety trial in healthy overweight adults found no significant body-composition changes [27]. NAD+ itself is a coenzyme involved in energy metabolism — there is no established mechanism by which supplemental NAD+ precursors cause weight gain, and no trial data to suggest it.